secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001493152-25-008203
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte adds Northwestern's Lurie Cancer Center as second site for LB-100 + Dostarlimab trial in ovarian clear cell cancer
--------------------------------------------------------------------------------

- Lurie Cancer Center (Northwestern University) opened as second clinical site for LB-100 plus GSK's Dostarlimab.
- First patient dosed at Lurie; patient recruitment is underway. Lead investigator: Dr. Emily M. Hinchcliff.
- Trial originally began in January 2024 at MD Anderson Cancer Center; lead investigator Dr. Amir Jazaeri.
- Trial targets ovarian clear cell carcinoma, a disease with high unmet medical need.
- LIXTE's proprietary compound LB-100 is combined with immunotherapy to enhance effectiveness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315225008203/0001493152-25-008203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315225008203/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-008203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer